Cyclo Therapeutics, Inc. (NASDAQ:CYTH) Sees Significant Increase in Short Interest

Cyclo Therapeutics, Inc. (NASDAQ:CYTH) was the recipient of a large increase in short interest during the month of April. As of April 15th, there was short interest totalling 75,300 shares, an increase of 65.1% from the March 31st total of 45,600 shares. Based on an average daily volume of 106,700 shares, the days-to-cover ratio is currently 0.7 days. Currently, 0.5% of the shares of the company are short sold.

Cyclo Therapeutics Stock Performance

Shares of Cyclo Therapeutics stock opened at $1.30 on Friday. The company has a market cap of $37.33 million, a P/E ratio of -0.99 and a beta of -0.15. Cyclo Therapeutics has a one year low of $0.84 and a one year high of $2.57. The firm has a fifty day moving average of $1.48 and a two-hundred day moving average of $1.46.

Cyclo Therapeutics (NASDAQ:CYTH) last announced its quarterly earnings data on Monday, March 18th. The company reported ($0.23) EPS for the quarter. The firm had revenue of $0.31 million for the quarter. Cyclo Therapeutics had a negative return on equity of 4,506.97% and a negative net margin of 1,864.03%.

Hedge Funds Weigh In On Cyclo Therapeutics

A hedge fund recently bought a new stake in Cyclo Therapeutics stock. Founders Fund V Management LLC purchased a new stake in Cyclo Therapeutics, Inc. (NASDAQ:CYTH) in the fourth quarter, according to the company in its most recent filing with the SEC. The firm purchased 480,708 shares of the company’s stock, valued at approximately $764,000. Cyclo Therapeutics makes up about 80.8% of Founders Fund V Management LLC’s investment portfolio, making the stock its biggest holding. Founders Fund V Management LLC owned 2.11% of Cyclo Therapeutics at the end of the most recent quarter. 68.55% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Separately, Ascendiant Capital Markets initiated coverage on shares of Cyclo Therapeutics in a research report on Monday, April 22nd. They set a “buy” rating and a $2.60 price objective for the company.

About Cyclo Therapeutics

Cyclo Therapeutics, Inc, a clinical stage biotechnology company, engages in the development of cyclodextrin-based products for the treatment of neurodegenerative diseases. The company's lead drug candidate is Trappsol Cyclo (hydroxypropyl beta cyclodextrin), an orphan drug, which is in Phase III clinical trials for the treatment of Niemann-Pick Type C disease; and in Phase IIb clinical trials for the treatment of Alzheimer's disease.